scispace - formally typeset
M

Michael J. Lodes

Researcher at CombiMatrix

Publications -  75
Citations -  3997

Michael J. Lodes is an academic researcher from CombiMatrix. The author has contributed to research in topics: Antigen & Epitope. The author has an hindex of 32, co-authored 75 publications receiving 3873 citations. Previous affiliations of Michael J. Lodes include GlaxoSmithKline & Corixa Corporation.

Papers
More filters
Journal ArticleDOI

Bacterial flagellin is a dominant antigen in Crohn disease

TL;DR: Serological expression cloning was used to identify commensal bacterial proteins that could contribute to the pathogenesis of IBD and identify flagellins as a class of immunodominant antigens that stimulate pathogenic intestinal immune reactions in genetically diverse hosts.
Journal ArticleDOI

Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

TL;DR: Serum responses to CBir1 independently identify a unique subset of patients with complicated CD patients, and this bacterial antigen was identified in a murine model and has a similar pattern of aberrant reactivity in a subset of CD patients.
Journal ArticleDOI

Detection of Cancer with Serum miRNAs on an Oligonucleotide Microarray

TL;DR: It is shown that sufficient miRNAs are present in one milliliter of serum to detect miRNA expression patterns, without the need for amplification techniques, and that these expression patterns are able to correctly discriminate between normal and cancer patient samples.
Journal ArticleDOI

Propionibacterium acnes Types I and II Represent Phylogenetically Distinct Groups

TL;DR: The study demonstrates that the phenotypic differences between P. acnes types I and II reflect deeper differences in their phylogeny, and nucleotide sequencing provides an accurate method for identifying the type status of P. Acnes isolates.
Journal ArticleDOI

CombiMatrix oligonucleotide arrays: genotyping and gene expression assays employing electrochemical detection.

TL;DR: The ElectraSense platform has been used to develop nucleic acid assays for highly accurate genotyping of a variety of pathogens including bio-threat agents and common pathogens of the respiratory tract.